The stock of Regulus Therapeutics Inc (NASDAQ:RGLS) is a huge mover today! About 302,986 shares traded hands. Regulus Therapeutics Inc (NASDAQ:RGLS) has declined 55.19% since March 2, 2016 and is downtrending. It has underperformed by 63.44% the S&P500.
The move comes after 6 months positive chart setup for the $184.68 million company. It was reported on Oct, 5 by Barchart.com. We have $10.32 PT which if reached, will make NASDAQ:RGLS worth $350.89M more.
Analysts await Regulus Therapeutics Inc (NASDAQ:RGLS) to report earnings on November, 3. They expect $-0.38 EPS, down 52.00% or $0.13 from last year’s $-0.25 per share. After $-0.40 actual EPS reported by Regulus Therapeutics Inc for the previous quarter, Wall Street now forecasts -5.00% EPS growth.
Regulus Therapeutics Inc (NASDAQ:RGLS) Ratings Coverage
Out of 5 analysts covering Regulus Therapeutics (NASDAQ:RGLS), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Regulus Therapeutics has been the topic of 9 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The rating was maintained by Chardan Capital Markets on Tuesday, June 7 with “Buy”. The rating was maintained by Wedbush on Wednesday, August 5 with “Buy”. BMO Capital Markets initiated Regulus Therapeutics Inc (NASDAQ:RGLS) rating on Tuesday, April 12. BMO Capital Markets has “Outperform” rating and $16 price target. Chardan Capital Markets maintained the stock with “Buy” rating in Tuesday, June 28 report. The firm has “Market Perform” rating given on Tuesday, June 28 by BMO Capital Markets. Wells Fargo initiated the shares of RGLS in a report on Friday, December 4 with “Outperform” rating. Needham maintained it with “Buy” rating and $10 target price in Tuesday, June 28 report. The rating was initiated by Chardan Capital Markets on Wednesday, April 13 with “Buy”.
According to Zacks Investment Research, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California.”
Insitutional Activity: The institutional sentiment increased to 1.23 in Q2 2016. Its up 0.19, from 1.04 in 2016Q1. The ratio is positive, as 26 funds sold all Regulus Therapeutics Inc shares owned while 14 reduced positions. 6 funds bought stakes while 43 increased positions. They now own 27.05 million shares or 18.99% less from 33.39 million shares in 2016Q1.
Teachers Retirement Of The State Of Kentucky holds 0% or 108,900 shares in its portfolio. Abingworth Llp reported 327,350 shares or 0.99% of all its holdings. The Illinois-based Northern has invested 0% in Regulus Therapeutics Inc (NASDAQ:RGLS). Manufacturers Life Insurance The last reported 29,471 shares in the company. Tiaa Cref Investment Limited Company accumulated 125,428 shares or 0% of the stock. Rhumbline Advisers last reported 0% of its portfolio in the stock. The New Jersey-based Sabby Mgmt Limited has invested 0.01% in Regulus Therapeutics Inc (NASDAQ:RGLS). Axa reported 1.05 million shares or 0.01% of all its holdings. Blackrock Group Limited has 7,349 shares for 0% of their US portfolio. Blackrock Lc has 0% invested in the company for 16,099 shares. Aperio Lc holds 11,360 shares or 0% of its portfolio. Spark Investment Mngmt Ltd Liability Com has 65,900 shares for 0.02% of their US portfolio. Metropolitan Life Insur Communications Ny accumulated 0% or 32,051 shares. Legal & General Group Plc last reported 0% of its portfolio in the stock. Barclays Public Limited Company holds 0% or 7,410 shares in its portfolio.
More notable recent Regulus Therapeutics Inc (NASDAQ:RGLS) news were published by: Streetinsider.com which released: “Regulus Therapeutics (RGLS) Names Timothy Wright Chief Research and …” on October 05, 2016, also Fool.com with their article: “Regulus Therapeutics Inc. Clinical Hold: Should Investors Be Yellow-Bellied?” published on June 28, 2016, Fool.com published: “Why Regulus Therapeutics Inc. Fell 20.1% in April” on May 10, 2016. More interesting news about Regulus Therapeutics Inc (NASDAQ:RGLS) were released by: Marketwatch.com and their article: “Regulus Therapeutics’ stock set to fall after FDA places hepatitis C treatment …” published on June 27, 2016 as well as Prnewswire.com‘s news article titled: “Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” with publication date: June 28, 2016.
RGLS Company Profile
Regulus Therapeutics Inc., incorporated on September 5, 2007, is a biopharmaceutical firm focused on discovering and developing drugs that target microribonucleic acid (microRNAs) to treat a range of diseases. The Firm uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company’s Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical firm to explore microRNAs as biomarkers for specific patient populations.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.